Celcuity Inc.（CELC）股票分析CELCCelcuity Inc.

Celcuity Inc. is a clinical-stage biotechnology company, which develops targeted therapies for the treatment of multiple solid tumor indications. Its lead therapeutic candidate is gedatolisib, a kinase inhibitor of phosphatidylinositol 3-kinase (PI3K), serine/threonine-protein kinase protein kinase B (AKT), mechanistic target of rapamycin (mTOR) pathway that binds to all class I PI3K isoforms and the mTOR complexes, mTORC1 and mTORC2. A Phase III clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) (HR+/HER2-) advanced breast cancer (ABC) has completed enrollment and reported detailed results for cohort 1, patients with PIK3CA wild-type (WT) tumors, and has completed enrollment of cohort 2, patients with PIK3CA mutant-type (MT) tumors. It operates in the Healthcare sector (SERVICES-MEDICAL LABORATORIES industry).

Celcuity Inc is not a good buy right now due to its current price of $56.58, which is significantly below analyst price targets ranging from $155 to $178. However, the stock has experienced a drastic decline of 43.73% year-to-date and a 16.72% drop over the last five days, indicating negative momentum. The RSI is at a very low 12.776, suggesting oversold conditions, but the company is facing substantial financial losses, with a net income of -$78,864,000 in Q2 2026 and a forward P/E ratio of 0, indicating no earnings growth expected in the near term. The main risk is the ongoing negative earnings trend, which has resulted in a consistent decline in net income over the past quarters.

1 analysts cover CELC: 1 rate it Buy, 0 Hold and 0 Sell. The average price target is 106.50.